CCAR1 expression is reduced in poorly differentiated breast cancers and FADD expression is downregulated during thyroid adenocarcinoma progression, with both cancers showing aberrant PI3K/AKT/mTORC1 pathway activation [54, 55]. This evidence concerns the gene CCAR1 and breast carcinoma.